MiRTeL CO., LTD.
- Representative Director CEO & Presindet：
- Eiji Tahara
The forefront of Medical innovation: to prevent diseases, increase the life expectancy and reduce medical expenditure.
MiRTeL was established by Professor Hidetoshi Tahara of Hiroshima University. The goal of the company is to contribute to the health and longevity of a society and to reduce medical costs by using the novel MiRTeL test. The “MirTeL tests” consist of the “Telomere test” and “MiR test”, which are minimally invasive diagnostic (less pain and more convenience) blood tests that can detect diseases at a far earlier stage compared to conventional blood tests. The Telomere G tail length measurement test is the only technique available for the prevention of diseases. The microRNA measurement test is a unique and Japan’s first disease-specific technique for the early detection of diseases. MiRTeL also has a future plan to create a disease prevention program to follow-up their test.
MiRTeL was established by Prof. Hidetoshi Tahara of Hiroshima University. Prof. Tahara realized the importance of practical applications of basic research when he was faced with the loss of his co-worker who died of juvenile gastric cancer. He developed the G tail length measurement technology for pre-symptomatic test. Furthermore, he endeavors to realize a society of health and longevity through early detection tests with micro RNA.
The first ''pre-symptomatic test'' in the world using the telomere G tail length measurement technology and "early detection of disease" through the examination of unique disease-specific microRNA in body fluids.
UTEC value up
Supporting the company in business planning and strategies, funding, human resources management, intellectual property advisory, and license contract execution.